My ePortfolio Register   

Certain factors may predict lung cancer patients' response to chemotherapy

In a retrospective analysis of 73 lung squamous cell carcinoma patients treated with the chemotherapy regimen of gemcitabine plus cisplatin, higher body mass index and younger age were linked with longer progression-free survival, the length of time that a patient lives with cancer but it does not get worse.

Patients with better response to treatment and higher body mass index had longer overall survival in the Thoracic Cancer analysis.

"Patients' clinical pathological characteristics may be used to predict the therapeutic efficacy of chemotherapy and survival," the authors wrote.

Source: Wiley

0

Comments

Please click on the 'New Comment' link to the left to add a new comment, or alternatively click any 'Add Comment' link next to any existing post to respond. The views expressed here are not those of ecancer. For more information please view our Privacy Policy.



Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

Cancer Intelligence